Super Session 4 – Cancer Precision Medicine: state-of-the-art and future directions

Emerging treatments, diagnostics and digital solutions: how they are impacting R&D and patient care?

Super Session 4 – Cancer Precision Medicine: state-of-the-art and future directions

10:45 - 12:15 Plenary Room A

The global oncology pipeline is growing at an unprecedented rate, the number of approved therapies continues to rise and advances in cancer immunotherapy, novel cell and gene therapies offer novel therapeutic options. At the same time, big data, AI and digital solutions are changing drug development, diagnostics and patient care. In this forward-looking session international experts will highlight recent advances and illustrate these with case studies and examples. They will share their perspectives on how precise and personalized today’s approaches really are and how different technologies and new collaborations can address existing challenges and limitations.

Hosted by:

Oslo Cancer Cluster

Oslo Cancer Cluster

Sponsored by:

Ferring Pharmaceuticals

Ferring Pharmaceuticals

Moderator(s): Dr. Gaspar Taroncher-Oldenburg - Editor-at-Large, Nature Publishing Group

Speaker(s):
Dr. Mark Swindells - Chief Operating Officer, Exscientia Ms. Kaisa Helminen - CEO, Aiforia Technologies Dr. Jørn Skibsted Jakobsen - Vice President, Global Clinical Research and Development, Ferring Pharmaceuticals Mr. Marko Kuisma - Chief Commercial Officer, Kaiku Health Prof. Carl Borrebaeck - Professor, Lund University Prof. Kristian Pietras - Professor of Molecular Medicine, Lund University Dr. George Coukos - Director Department of Oncology, University of Lausanne

full program